Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI

Exclusion Criteria

• •Patient is under consideration for or has undergone a successful bone marrow transplant (BMT).
• •Pregnant or lactating patient
• •Patient has received an investigational drug within 30 days prior to study enrollment
• •Patient has been previously treated with rhASB
• •Patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly confound study results or decrease study compliance
• •Patient has a known hypersensitivity to rhASB or to components of the study drug
• •History of cancer (except low grade and fully resolved skin malignancy)